Comparison of Three Chemotherapy Protocols With Electrochemotherapy for the Treatment of Feline Cutaneous Squamous Cell Carcinoma.

Autor: Diop N; Université de Lyon, VetAgro Sup, Service de cancérologie, UR ICE, Marcy l'Etoile, France., Sayag D; ONCOnseil-Unité d'expertise en oncologie vétérinaire, Toulouse, France., Marques GB; Université de Lyon, VetAgro Sup, Service de cancérologie, UR ICE, Marcy l'Etoile, France., Chamel G; Université de Lyon, VetAgro Sup, Service de cancérologie, UR ICE, Marcy l'Etoile, France., Chavalle T; Université de Lyon, VetAgro Sup, Service de cancérologie, UR ICE, Marcy l'Etoile, France., Eon JB; Université de Lyon, VetAgro Sup, Service de cancérologie, UR ICE, Marcy l'Etoile, France., Floch F; AniCura TRIOVet, Rennes, France., Lajoinie M; Université de Lyon, VetAgro Sup, Service de cancérologie, UR ICE, Marcy l'Etoile, France., Ponce F; Université de Lyon, VetAgro Sup, Service de cancérologie, UR ICE, Marcy l'Etoile, France., Barrett LE; Université de Lyon, VetAgro Sup, Service de cancérologie, UR ICE, Marcy l'Etoile, France.
Jazyk: angličtina
Zdroj: Veterinary and comparative oncology [Vet Comp Oncol] 2024 Sep; Vol. 22 (3), pp. 437-446. Date of Electronic Publication: 2024 Jul 15.
DOI: 10.1111/vco.12995
Abstrakt: Electrochemotherapy (ECT) with intravenous (IV) and/or intratumoral (IT) bleomycin has shown considerable efficacy in the treatment of non-resectable feline cutaneous squamous cell carcinoma (cSCC), boasting response rates of up to 95%, but other chemotherapy protocols have not yet been investigated. The objective of this prospective multicentre study was to compare the overall response rate (ORR) and progression-free interval (PFI) between cats with cSCC treated with ECT using IT and IV carboplatin (IV + IT), IV carboplatin (IV) or IV bleomycin (IV). A total of 44 cats with unresectable cSCC across three centres were enrolled and treated with ECT using carboplatin IV + IT (n = 10), carboplatin IV (n = 11) or bleomycin IV (n = 23). Treatment response according to RECIST criteria was recorded at 2 and 4 weeks post-treatment, and patients were followed until disease progression and/or death. All three groups were comparable regarding age, sex, weight, and lesion size. Adverse events were generally mild, localised and similar between groups. ORRs were 90.0% (carboplatin IV + IT), 90.9% (carboplatin IV) and 95.6% (bleomycin IV) and were not significantly different (p = 0.79). Median PFI was not reached for carboplatin IV + IT or carboplatin IV and was 566 days for bleomycin IV, with no significant difference between the three groups (p = 0.81). This study suggests that ECT using IV or IV + IT carboplatin is a reasonable alternative therapeutic option for managing cSCC, and further studies are warranted to compare outcomes between treatment protocols.
(© 2024 The Author(s). Veterinary and Comparative Oncology published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: